Clinical Trials Logo

Metabolic Syndrome clinical trials

View clinical trials related to Metabolic Syndrome.

Filter by:

NCT ID: NCT00273572 Completed - Diabetes Clinical Trials

Lifestyle Intervention in Obese Arab Women

Start date: December 2004
Phase: N/A
Study type: Interventional

The study protocol aims to test the hypothesis that a lifestyle intervention program aimed to increase leisure-time physical activity and reduce body weight will improve the parameters of the metabolic syndrome and quality of life among obese, non-diabetic Arab women

NCT ID: NCT00272311 Completed - Clinical trials for Cardiovascular Diseases

Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome

PAD
Start date: October 2006
Phase: Phase 4
Study type: Interventional

The purpose of the study is to test higher versus lower doses of aspirin on markers of atherosclerosis in patients at risk of a first heart attack.

NCT ID: NCT00271921 Completed - Metabolic Syndrome Clinical Trials

Does Metabolic Syndrome Exist in Anorexia Nervosa?

Start date: September 2005
Phase: N/A
Study type: Observational

The purpose of this study is to examine whether body fat distribution changes that occur with weight gain in women recovering from anorexia nervosa are transient or persistent, and if they are associated with other features of Metabolic Syndrome.

NCT ID: NCT00270985 Completed - Metabolic Syndrome Clinical Trials

The Metabolic Effects of Almond Consumption in Adults With Pre-Diabetes

Start date: January 2006
Phase: Phase 1
Study type: Interventional

Study Hypothesis: Daily consumption of almonds over 16 weeks will produce a decrease in hemoglobin A1c (HbA1c) levels in adults with pre-diabetes. Lay Summary: Persons developing type 2 diabetes mellitus (T2DM) will typically first have a condition called pre-diabetes. Lifestyle is a major factor that determines whether pre-diabetes becomes full T2DM. Lifestyle includes dietary habits and physical activity. Many people develop T2DM because of poor dietary habits and a sedentary lifestyle. Moreover, eating a high-fat, high-sugar diet can damage the blood vessels and increase the risk of strokes and heart attacks. A person's diet may produce substances in the blood that can interfere with the production of insulin in the pancreas. Sometimes, these changes in the insulin producing cells are serious and can eventually interfere with how the cells in the body use blood sugar, which causes T2DM. Techniques are available to measure circulating substances in the blood of persons with pre-diabetes that may be associated with the development of T2DM. Laboratory research has shown that almonds contain high levels of important compounds that may influence the onset of heart disease and T2DM. A meal plan that includes almonds daily will be given to half of the study participants and the other participants will be given a meal plan that is "nut-free". Because of the potential to delay the onset of heart disease and T2DM in some persons with pre-diabetes, this 16-week study will collect and analyze blood samples for changes that may make the person with pre-diabetes more likely to develop heart disease and T2DM. Blood samples will be collected at weeks 0, 8 and 16 to measure compounds that may be influenced by consuming almonds daily. This study will also attempt to understand other possible causes of heart disease and T2DM in persons with pre-diabetes; particularly those that might be related to body weight and body composition. Body composition techniques using very small amounts of electrical current are available to study body fat. Body weight, waist and hip measurements, blood pressure and body composition testing will be performed at the start of the study and every 4 weeks during the study. Lastly, these other possible causes of heart disease and T2DM will be investigated to look at relationships with the substances in the blood.

NCT ID: NCT00266292 Active, not recruiting - Metabolic Syndrome Clinical Trials

The Effect of n-3 LCPUFA on Immune Function and Cardiovascular Risk Factors

Start date: September 2005
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effects of long-chain n-3 polyunsaturated fatty acids (n-3 LCPUFA) on immune function and cardiovascular disease risk

NCT ID: NCT00242814 Completed - Hypertension Clinical Trials

Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities

Start date: November 3, 2005
Phase: Phase 4
Study type: Interventional

The objective of the study is to compare PPAR activities (increase of adiponectin level) between MICARDIS and amlodipine after 6 weeks of treatment in hypertensive patients with metabolic syndrome. Moreover, this study will compare serum level of inflammatory markers of the metabolic syndrome after 6 weeks of treatment. An ancillary study performed in one center will assess adipocyte differentiation (PPAR gamma stimulation) in 30 subjects (15 per arm).

NCT ID: NCT00241150 Completed - Hypertension Clinical Trials

Diva - The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial Function In Hypertensive Subjects With The Metabolic Syndrome

Start date: November 2002
Phase: Phase 4
Study type: Interventional

A STUDY ON WHETHER AN ANTIHYPERTENSIVE MEDICATION PREVENTS DAMAGE TO WALLS OF VEINS IN FEMALE PATIENTS WITH THE METABOLIC SYNDROME (OVERWEIGHT AND OTHER DISORDERS).

NCT ID: NCT00240305 Completed - Metabolic Syndrome Clinical Trials

A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome

Start date: April 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the dose-related effect of treatment with rosuvastatin on production and fractional catabolism of apolipoprotein A-I (apoA-I) and apolipoprotein A-II (apoA-II), and on the plasma apoA-I, apoA-II and high-density lipoprotein cholesterol (HDL-C) concentration.

NCT ID: NCT00240266 Completed - Metabolic Syndrome Clinical Trials

Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTORâ„¢) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)

Start date: August 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the effect of treatment with rosuvastatin on the capacity of plasma to promote cholesterol efflux, which is the first and likely rate limiting step in reverse cholesterol transport.

NCT ID: NCT00234858 Completed - Hypertension Clinical Trials

Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)

STAR
Start date: March 2004
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to determine whether impaired glucose tolerance is improved to a greater degree by Tarka than Hyzaar in subjects with metabolic syndrome